CN105669597B - 淀粉状蛋白结合剂 - Google Patents

淀粉状蛋白结合剂 Download PDF

Info

Publication number
CN105669597B
CN105669597B CN201511023642.4A CN201511023642A CN105669597B CN 105669597 B CN105669597 B CN 105669597B CN 201511023642 A CN201511023642 A CN 201511023642A CN 105669597 B CN105669597 B CN 105669597B
Authority
CN
China
Prior art keywords
unsubstituted
substituted
compound
amyloid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201511023642.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105669597A (zh
Inventor
杰里·杨
伊曼纽尔·A·塞奥多拉基斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN105669597A publication Critical patent/CN105669597A/zh
Application granted granted Critical
Publication of CN105669597B publication Critical patent/CN105669597B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201511023642.4A 2009-12-10 2010-12-10 淀粉状蛋白结合剂 Active CN105669597B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28547009P 2009-12-10 2009-12-10
US61/285,470 2009-12-10
CN201080062250.8A CN103201258B (zh) 2009-12-10 2010-12-10 淀粉状蛋白结合剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080062250.8A Division CN103201258B (zh) 2009-12-10 2010-12-10 淀粉状蛋白结合剂

Publications (2)

Publication Number Publication Date
CN105669597A CN105669597A (zh) 2016-06-15
CN105669597B true CN105669597B (zh) 2019-05-07

Family

ID=44146211

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201511023642.4A Active CN105669597B (zh) 2009-12-10 2010-12-10 淀粉状蛋白结合剂
CN201080062250.8A Active CN103201258B (zh) 2009-12-10 2010-12-10 淀粉状蛋白结合剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080062250.8A Active CN103201258B (zh) 2009-12-10 2010-12-10 淀粉状蛋白结合剂

Country Status (25)

Country Link
US (3) US8940918B2 (enExample)
EP (1) EP2509940B1 (enExample)
JP (1) JP5591946B2 (enExample)
KR (3) KR102079160B1 (enExample)
CN (2) CN105669597B (enExample)
AU (1) AU2010327918B2 (enExample)
BR (1) BR112012013810B1 (enExample)
CA (1) CA2783466C (enExample)
CY (1) CY1116487T1 (enExample)
DK (1) DK2509940T3 (enExample)
ES (1) ES2546063T3 (enExample)
HR (1) HRP20150854T1 (enExample)
HU (1) HUE027199T2 (enExample)
IN (1) IN2012DN05186A (enExample)
ME (1) ME02194B (enExample)
MX (1) MX347591B (enExample)
NZ (1) NZ600459A (enExample)
PL (1) PL2509940T3 (enExample)
PT (1) PT2509940E (enExample)
RS (1) RS54158B1 (enExample)
RU (1) RU2517174C2 (enExample)
SG (1) SG181561A1 (enExample)
SI (1) SI2509940T1 (enExample)
SM (1) SMT201500216B (enExample)
WO (1) WO2011072257A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180815A1 (en) * 2012-05-30 2013-12-05 University Of Tennessee Research Foundation Compounds for amide-forming reactions
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
TW201609183A (zh) * 2013-10-31 2016-03-16 康諾普堤克斯公司 眼用調配物之製備方法及其用途
CA2930112A1 (en) * 2013-11-12 2015-05-21 Cognoptix, Inc. Method for measuring fluorescence in ocular tissue
JP2017512834A (ja) * 2014-03-19 2017-05-25 アミディス・ダイアグノスティックス・インコーポレイテッド アミロイド標的剤及びその使用方法
CA2960723A1 (en) * 2014-09-12 2016-03-17 Amydis Diagnostics, Inc. In vitro compositions comprising human sample and amyloid targeting agent
US11286233B2 (en) 2017-05-09 2022-03-29 Ambient Photonics, Inc. Stilbene derivatives for the treatment of CNS and other disorders
EP3803416A4 (en) * 2018-05-31 2022-05-18 Amydis, Inc. COMPOSITIONS AND METHODS FOR DETECTING BRAIN TRAUMA
CA3118325A1 (en) * 2018-11-02 2020-05-07 Amydis, Inc. Phosphate compounds for detecting neurological disorders
AU2022234434A1 (en) * 2021-03-12 2023-09-14 Amydis, Inc. Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein
CN115322165A (zh) * 2022-09-30 2022-11-11 镇江百单医疗生物科技有限公司 近红外荧光探针成像肝纤维化中亚铁离子的动态波动

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
CN101209976A (zh) * 2006-12-29 2008-07-02 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
CN101506231A (zh) * 2006-08-18 2009-08-12 瑟维尔实验室 筛选具有抗淀粉样蛋白性质的化合物的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583614A (en) * 1950-05-13 1952-01-29 Eastman Kodak Co Acylated methine dye compounds
US2798090A (en) * 1953-03-02 1957-07-02 Eastman Kodak Co Process for preparing benzalaniline-3-sulfonic acid compounds
US3074971A (en) * 1959-01-23 1963-01-22 Gen Aniline & Film Corp alpha-cyanocinnamic acid esters
US3149146A (en) * 1960-03-09 1964-09-15 Gen Aniline & Film Corp Alpha-cyano-2-alkenoxy-1-naphthaleneacrylic acid esters
FR1321641A (fr) 1962-03-08 1963-03-22 Gen Aniline & Film Corp Nouvelles compositions absorbantes de rayons ultraviolets
BE794010A (fr) * 1972-01-13 1973-05-02 Du Pont Colorants cationiques de couleur jaune-vert
DE2714653C3 (de) 1977-04-01 1980-10-30 Bayer Ag, 5090 Leverkusen Kationische Styrylfarbstoffe und Verfahren zum Färben mit diesen Farbstoffen
DE2942185A1 (de) * 1979-10-18 1981-04-30 Basf Ag, 6700 Ludwigshafen Basische farbstoffe
JPS5815912A (ja) * 1981-07-22 1983-01-29 Ss Pharmaceut Co Ltd 消炎鎮痛剤
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63163826A (ja) * 1986-12-26 1988-07-07 Idemitsu Kosan Co Ltd 有機非線型光学材料
DE3905916A1 (de) * 1989-02-25 1990-08-30 Basf Ag Verwendung von derivaten des n-phenyl-3,4,5,6-tetrahydrophthalimids zur desikkation und abszission von pflanzenorganen
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4430691A1 (de) * 1994-08-30 1996-03-07 Bayer Ag Elektrolumineszierende Anordnungen und deren Verwendung
BR0307000A (pt) * 2002-01-18 2004-11-03 Hospital For Sick Children Compostos para modulação de proliferação celular
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
MXPA05009434A (es) * 2003-03-05 2005-11-23 Celgene Corp Compuestos de difeniletileno y usos de los mismos.
US7517695B2 (en) * 2004-01-20 2009-04-14 The Curators Of The University Of Missouri Local flow and shear stress sensor based on molecular rotors
US7598419B2 (en) * 2004-03-26 2009-10-06 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
US7666886B2 (en) 2005-07-15 2010-02-23 The Regents Of The University Of California Compounds and methods for the diagnosis and treatment of amyloid associated diseases
US8895791B2 (en) 2006-07-31 2014-11-25 Basf Se Method of regenerating ruthenium catalysts suitable for hydrogenation
WO2009052837A2 (en) * 2007-10-24 2009-04-30 Tallinn University Of Technology Maldi ms-based high-throughput screening method for substances inhibiting aggregation of alzheimer's amyloid beta peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
CN101506231A (zh) * 2006-08-18 2009-08-12 瑟维尔实验室 筛选具有抗淀粉样蛋白性质的化合物的方法
CN101209976A (zh) * 2006-12-29 2008-07-02 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途

Also Published As

Publication number Publication date
US9551722B2 (en) 2017-01-24
IN2012DN05186A (enExample) 2015-10-23
AU2010327918A1 (en) 2012-06-21
CA2783466A1 (en) 2011-06-16
WO2011072257A2 (en) 2011-06-16
US20120302603A1 (en) 2012-11-29
AU2010327918B2 (en) 2014-01-16
DK2509940T3 (en) 2015-07-20
RS54158B1 (sr) 2015-12-31
PL2509940T3 (pl) 2015-11-30
SMT201500216B (it) 2015-10-30
CN103201258A (zh) 2013-07-10
MX2012006552A (es) 2012-08-23
US20150177262A1 (en) 2015-06-25
KR20190109594A (ko) 2019-09-25
KR101849680B1 (ko) 2018-04-17
ES2546063T3 (es) 2015-09-18
KR20180041767A (ko) 2018-04-24
BR112012013810B1 (pt) 2022-01-11
CA2783466C (en) 2019-09-24
EP2509940A4 (en) 2013-04-17
CN103201258B (zh) 2016-01-27
CN105669597A (zh) 2016-06-15
HK1177930A1 (en) 2013-08-30
US8940918B2 (en) 2015-01-27
KR102079160B1 (ko) 2020-02-19
RU2517174C2 (ru) 2014-05-27
US20170315137A1 (en) 2017-11-02
HK1225729A1 (zh) 2017-09-15
SG181561A1 (en) 2012-07-30
CY1116487T1 (el) 2017-03-15
RU2012128798A (ru) 2014-01-20
NZ600459A (en) 2014-01-31
EP2509940B1 (en) 2015-06-10
EP2509940A2 (en) 2012-10-17
JP2013513619A (ja) 2013-04-22
PT2509940E (pt) 2015-09-24
WO2011072257A3 (en) 2011-10-20
JP5591946B2 (ja) 2014-09-17
SI2509940T1 (sl) 2015-09-30
ME02194B (me) 2016-02-20
HUE027199T2 (en) 2016-08-29
MX347591B (es) 2017-05-03
KR20120104306A (ko) 2012-09-20
BR112012013810A2 (pt) 2020-08-25
HRP20150854T1 (hr) 2015-09-25

Similar Documents

Publication Publication Date Title
CN105669597B (zh) 淀粉状蛋白结合剂
ES3044433T3 (en) Compositions for use in a method of treating an estrogen receptor associated cancer
DK2989110T3 (en) Tamoxifen derivatives for the treatment of neoplastic diseases, especially with high HER2 protein levels
CN108727363B (zh) 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
EP3298015B1 (en) Pyrazolopyrimidine derivatives
CN103159760A (zh) 作为cftr调控剂的氮杂吲哚衍生物
Bu et al. Synthesis of 5α, 8α‐Ergosterol Peroxide 3‐Carbamate Derivatives and a Fluorescent Mitochondria‐Targeting Conjugate for Enhanced Anticancer Activities
CN105566302B (zh) 二氢吲哚酮化合物及其盐的结晶
JP7652791B2 (ja) α－シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物
HK1225729B (zh) 淀粉状蛋白结合剂
HK1177930B (en) Amyloid binding agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225729

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant